Phase II multicentric study to evaluate the efficacy and the safety of Bendamustine in adjunct to Etoposide, Aracytabin and Melphalan (BeEAM) as a preparative regimen for autologous stem cell transplantation in refractory/relapsed aggressive B-cell non-Hodgkin lymphoma patients [Studio di fase II, multicentrico, per valutare la sicurezza e l'efficacia di Bendamustina in aggiunta a Etoposide, Citosina Arabinoside e Melphalan come regime di condizionamento al trapianto autologo in pazienti affetti da linfoma non-Hodgkin B aggressivo ricaduti/resistenti]

Trial Profile

Phase II multicentric study to evaluate the efficacy and the safety of Bendamustine in adjunct to Etoposide, Aracytabin and Melphalan (BeEAM) as a preparative regimen for autologous stem cell transplantation in refractory/relapsed aggressive B-cell non-Hodgkin lymphoma patients [Studio di fase II, multicentrico, per valutare la sicurezza e l'efficacia di Bendamustina in aggiunta a Etoposide, Citosina Arabinoside e Melphalan come regime di condizionamento al trapianto autologo in pazienti affetti da linfoma non-Hodgkin B aggressivo ricaduti/resistenti]

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2014

At a glance

  • Drugs Bendamustine (Primary) ; Cytarabine; Etoposide; Melphalan
  • Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Oct 2012 Planned end date added (8 Jun 2016) as reported by European Clinical Trials Database record.
    • 02 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top